A Randomized, multicenter Clinical Trial to evaluate the safety and tolerability of Clozapine versus standard clinical practice in treatment-resistant psychosis in adolescents and young adults with intellectual disability
CLOZAID
EUDRACT 2020-000091-37
NCT04529226
A randomized, multicenter clinical trial to assess the safety and tolerability of clozapine vs treatment as usual for treatment-resistant psychosis in adolescents and young adults with intellectual disability.
End of recruitment: 31 Oct 2022
Sponsor: Carlos III Health Institute
Primary objective:
To evaluate the efficacy of clozapine vs usual clinical practice treatment in subjects with intellectual disability associated with a psychotic disorder on measures of scoring change from baseline in the ICG-SCH (The Clinical Global Impression–Schizophrenia scale) to the end of the study.
